Aarkstore - Cystic Fibrosis - Pipeline Review, H2 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Cystic Fibrosis - Pipeline Review, H2 2014

Description:

"Cystic Fibrosis - Pipeline Review, H2 2014"report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. – PowerPoint PPT presentation

Number of Views:71

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Cystic Fibrosis - Pipeline Review, H2 2014


1
Cystic Fibrosis - Pipeline Review, H2 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/63083/cystic-fibrosis-pipeline-review

2
Cystic Fibrosis - Pipeline Review, H2 2014
3
Summary
  • Global Markets Directs, Cystic Fibrosis -
    Pipeline Review, H2 2014, provides an overview
    of the Cystic Fibrosiss therapeutic
    pipeline. This report provides comprehensive
    information on the therapeutic development for
    Cystic Fibrosis, complete with comparative
    analysis at various stages, therapeutics
    assessment by drug target, mechanism of action
    (MoA), route of administration (RoA) and molecule
    type, along with latest updates, and featured
    news and press releases. It also reviews key
    players involved in the therapeutic development
    for Cystic Fibrosis and special features on
    late-stage and discontinued projects.
  • Global Markets Directs report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team.

4
Summary
  • Drug profiles/records featured in the report
    undergoes periodic updation following a stringent
    set of processes that ensures that all the
    profiles are updated with the latest set of
    information. Additionally, processes including
    live news deals tracking, browser based
    alert-box and clinical trials registries tracking
    ensure that the most recent developments are
    captured on a real time basis. The report
    enhances decision making capabilities and help to
    create effective counter strategies to gain
    competitive advantage. It strengthens RD
    pipelines by identifying new targets and MOAs to
    produce first-in-class and best-in-class
    products. Note Certain sections in the report
    may be removed or altered based on the
    availability and relevance of data for the
    indicated disease.

5
Scope
  • - The report provides a snapshot of the global
    therapeutic landscape of Cystic Fibrosis - The
    report reviews key pipeline products under drug
    profile section which includes, product
    description, MoA and RD brief, licensing and
    collaboration details other developmental
    activities  - The report reviews key players
    involved in the therapeutics development for
    Cystic Fibrosis and enlists all their major and
    minor projects - The report summarizes all the
    dormant and discontinued pipeline projects  - A
    review of the Cystic Fibrosis products under
    development by companies and universities/research
    institutes based on information derived from
    company and industry-specific sources - Pipeline
    products coverage based on various stages of
    development ranging from pre-registration till
    discovery and undisclosed stages - A detailed
    assessment of monotherapy and combination therapy
    pipeline projects - Coverage of the Cystic
    Fibrosis pipeline on the basis of target, MoA,
    route of administration and molecule type -
    Latest news and deals relating related to
    pipeline products

6
Reasons to buy
  • - Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies - Identify
    emerging players with potentially strong product
    portfolio and create effective counter-strategies
    to gain competitive advantage - Develop strategic
    initiatives by understanding the focus areas of
    leading companies - Identify and understand
    important and diverse types of therapeutics under
    development for Cystic Fibrosis - Plan mergers
    and acquisitions effectively by identifying key
    players of the most promising pipeline - Devise
    corrective measures for pipeline projects by
    understanding Cystic Fibrosis pipeline depth and
    focus of Indication therapeutics - Develop and
    design in-licensing and out-licensing strategies
    by identifying prospective partners with the most
    attractive projects to enhance and expand
    business potential and scope - Modify the
    therapeutic portfolio by identifying discontinued
    projects and understanding the factors that drove
    them from pipeline   

7
Table of Content
List of Tables 7 List of Figures 9 Introduction
10 Global Markets Direct Report Coverage
10 Cystic Fibrosis Overview 11 Therapeutics
Development 12 Pipeline Products for Cystic
Fibrosis - Overview 12 Pipeline Products for
Cystic Fibrosis - Comparative Analysis 13 Cystic
Fibrosis - Therapeutics under Development by
Companies 14 Cystic Fibrosis - Therapeutics under
Investigation by Universities/Institutes
18 Cystic Fibrosis - Pipeline Products Glance
20 Late Stage Products 20 Clinical Stage Products
21 Early Stage Products 22
8
Table of Content
Unknown Stage Products 23 Cystic Fibrosis -
Products under Development by Companies 24 Cystic
Fibrosis - Products under Investigation by
Universities/Institutes 29 Cystic Fibrosis -
Companies Involved in Therapeutics Development
30 Alaxia SAS 30 AlgiPharma AS 31 Bayer AG
32 Beech Tree Labs, Inc. 33 Carolus Therapeutics,
Inc. 34 Celsus Therapeutics Plc 35 Celtaxsys,
Inc. 36 Chiesi Farmaceutici SpA 37 Cilian AG
38 Concert Pharmaceuticals, Inc. 39 Corbus
pharmaceuticals, Inc. 40
9
List Of Tables
  • Number of Products under Development for Cystic
    Fibrosis, H2 2014 18 Number of Products under
    Development for Cystic Fibrosis - Comparative
    Analysis, H2 2014 19 Number of Products under
    Development by Companies, H2 2014 20 Number of
    Products under Development by Companies, H2 2014
    (Contd..2) 22 Number of Products under
    Development by Companies, H2 2014 (Contd..3)
    23 Number of Products under Investigation by
    Universities/Institutes, H2 2014 25 Comparative
    Analysis by Late Stage Development, H2 2014
    26 Comparative Analysis by Clinical Stage
    Development, H2 2014 27 Comparative Analysis by
    Early Stage Development, H2 2014 28 Comparative
    Analysis by Unknown Stage Development, H2 2014
    29 Products under Development by Companies, H2
    2014 30 Products under Development by Companies,
    H2 2014 (Contd..1) 31

10
List Of Tables
  • Products under Development by Companies, H2 2014
    (Contd..2) 32 Products under Development by
    Companies, H2 2014 (Contd..3) 33 Products under
    Development by Companies, H2 2014 (Contd..4)
    34 Products under Investigation by
    Universities/Institutes, H2 2014 35 Cystic
    Fibrosis - Pipeline by Alaxia SAS, H2 2014
    36 Cystic Fibrosis - Pipeline by AlgiPharma AS,
    H2 2014 37 Cystic Fibrosis - Pipeline by Bayer
    AG, H2 2014 38 Cystic Fibrosis - Pipeline by
    Beech Tree Labs, Inc., H2 2014 39 Cystic Fibrosis
    - Pipeline by Carolus Therapeutics, Inc., H2 2014
    40 Cystic Fibrosis - Pipeline by Celsus
    Therapeutics Plc, H2 2014 41 Cystic Fibrosis -
    Pipeline by Celtaxsys, Inc., H2 2014 42 Cystic
    Fibrosis - Pipeline by Chiesi Farmaceutici SpA,
    H2 2014 43 Cystic Fibrosis - Pipeline by Cilian
    AG, H2 2014 44
  • Cystic Fibrosis - Pipeline by Concert
    Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis -
    Pipeline by Corbus pharmaceuticals, Inc., H2 2014
    Cystic Fibrosis - Pipeline by Cubist
    Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis -
    Pipeline by DiscoveryBiomed, Inc., H2 2014 48

11
List of Figures
  • Number of Products under Development for Cystic
    Fibrosis, H2 2014 18 Number of Products under
    Development for Cystic Fibrosis - Comparative
    Analysis, H2 2014 19 Number of Products under
    Development by Companies, H2 2014 20 Number of
    Products under Investigation by
    Universities/Institutes, H2 2014 24 Comparative
    Analysis by Late Stage Development, H2 2014
    26 Comparative Analysis by Clinical Stage
    Development, H2 2014 27 Comparative Analysis by
    Early Stage Products, H2 2014 28 Assessment by
    Monotherapy Products, H2 2014 86 Number of
    Products by Top 10 Targets, H2 2014 88 Number of
    Products by Stage and Top 10 Targets, H2 2014
    88 Number of Products by Top 10 Mechanism of
    Actions, H2 2014 91 Number of Products by Stage
    and Top 10 Mechanism of Actions, H2 2014
    91 Number of Products by Top 10 Routes of
    Administration, H2 2014 94

12
Related Reports
  • Global Neurosurgery Market 2015-2019
  • BrainStorm Cell Therapeutics Inc. (BCLI) -
    Financial and Strategic SWOT Analysis Review
  • Ampio Pharmaceuticals, Inc. (AMPE) - Financial
    and Strategic SWOT Analysis Review
  • MiMedx Group, Inc (MDXG) - Financial and
    Strategic SWOT Analysis Review
  • Threshold Pharmaceuticals, Inc. (THLD) -
    Financial and Strategic SWOT Analysis Review

13
Related Reports
  • MEI Pharma, Inc. (MEIP) - Financial and Strategic
    SWOT Analysis Review
  • Titan Pharmaceuticals, Inc. (TTNP) - Financial
    and Strategic SWOT Analysis Review
  • RedHill Biopharma Ltd. (RDHL) - Financial and
    Strategic SWOT Analysis Review
  • Pharmaceuticals Healthcare Market Research
    Reports

14
  • Cystic Fibrosis - Pipeline Review, H2 2014
  • Published Oct 2014 267 Pages
  • Cystic Fibrosis - Pipeline Review, H2 2014 report
    features investigational drugs from across globe
    covering over 20 therapy areas and nearly 3,000
    indications. 
    Price

Format Price
PDF 2000
Site Licence 4000
Enterprise Wide Licence 6000
15
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com